This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sartori, S. Articles by Abbasciano, V. Search for Related Content PubMed PubMed Citation Articles by Sartori, S. Articles by Abbasciano, V.

Prospective Randomized Trial of Intrapleural Bleomycin Versus Interferon Alfa-2b via Ultrasound-Guided Small-Bore Chest Tube in the Palliative Treatment of Malignant Pleural Effusions

From the Section of Interventional Ultrasound and Department of Internal Medicine, St Anna Hospital, Ferrara; and the Division of Oncology, City Hospital, Rimini, Italy

Address reprint requests to Sergio Sartori, MD, Section of Interventional Ultrasound, Department of Internal Medicine, St Anna Hospital, corso Giovecca 203, I-44100 Ferrara, Italy; e-mail: srs{at}unife.it

PURPOSE: To compare bleomycin pleurodesis and immunotherapy with intrapleural interferon alfa-2b (IFN) in the palliation of malignant pleural effusions.

PATIENTS AND METHODS: One hundred sixty patients with rapidly recurrent malignant pleural effusion were randomly assigned to intrapleural bleomycin (83 patients) or IFN (77 patients). A 9-French intrapleural catheter was placed under sonographic guidance, and pleural effusion was completely drained before starting the treatment. Bleomycin 0.75 mg/kg was administered as a single dose. An additional dose was given if daily fluid output did not drop to less than 100 mL/d within 3 days. IFN 1 million units/10 kg was administered for six courses at 4-day intervals. Thirty-day and long-term responses were evaluated under the intention-to-treat principle.

RESULTS: Thirty-day response was 84.3% in the bleomycin arm and 62.3% in IFN arm (P = .002). Median time to progression was 93 days (range, 12 to 395 days) in bleomycin group, and 59 days (range, 7 to 292 days) in the IFN group (P < .001). Median survival was 96 days (range, 15 to 395) and 85 days (range, 16 to 292) in the bleomycin and IFN groups, respectively. Twenty-three patients received two doses of bleomycin, as their daily fluid output remained higher than 100 mL after the first dose. Thirteen of them had complete response, which lasted until death.

CONCLUSION: Intrapleural bleomycin is more effective than IFN and is a valid option for the palliative treatment of massive, rapidly recurrent malignant pleural effusions. The administration of a second dose of bleomycin to patients not responding to the first one can remarkably improve the overall outcome of the treatment.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				P. A. Kvale, P. A. Selecky, and U. B. S. Prakash Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 368S - 403S. [Abstract] [Full Text] [PDF]

				V. Steger, U. Mika, H. Toomes, T. Walker, C. Engel, T. Kyriss, G. Ziemer, and G. Friedel Who Gains Most? A 10-Year Experience With 611 Thoracoscopic Talc Pleurodeses Ann. Thorac. Surg., June 1, 2007; 83(6): 1940 - 1945. [Abstract] [Full Text] [PDF]

				S. Sartori, P. Tombesi, D. Tassinari, P. Ceccotti, I. Nielsen, L. Trevisani, and V. Abbasciano Sonographically Guided Small-Bore Chest Tubes and Sonographic Monitoring for Rapid Sclerotherapy of Recurrent Malignant Pleural Effusions J. Ultrasound Med., September 1, 2004; 23(9): 1171 - 1176. [Abstract] [Full Text] [PDF]